Dr Reddy's Receives DCGI Approval for Zytorvi in Advanced Esophageal Cancer
Dr Reddy's Laboratories has received approval from India's Drugs Controller General (DCGI) for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma (ESCC). The drug, used with cisplatin and paclitaxel, is approved for first-line treatment of unresectable, recurrent, or metastatic ESCC in adults. This expands Zytorvi's indications beyond nasopharyngeal carcinoma. Approval is based on Phase 3 JUPITER-06 trial results showing a 42% reduction in disease progression or death risk and improved median overall survival to 17.7 months versus 12.9 months with chemotherapy alone.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (65/100). Lens Score 42/100.
Outlets measured: news18, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 21 Oct, 05:57 am. Other outlets followed.
- 1